NCT04695106

Phase 4Interventional

Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.

View on ClinicalTrials.gov ↗

Timeline

Start date: Mar 1, 2021
Primary completion: Mar 1, 2024
Completion date: Mar 31, 2026
First posted: Jan 5, 2021
Last posted: Jan 5, 2021
Enrollment: 2230
Arms / groups: 2 / —
Source: AACT · ingestion pipeline

Sponsors

Medical University of GdanskLead sponsor
University of OpoleCollaborator
Bielanski HospitalCollaborator
Poznan UniversityCollaborator
Silesian University of MedicineCollaborator
Medical University of WarsawCollaborator
Medical University of LublinCollaborator
Pomeranian Medical UniversityCollaborator
Government of PolandCollaborator
Institute of Cardiology, Warsaw, PolandCollaborator
Nicolaus Copernicus UniversityCollaborator
Medical University of GdanskReponsible party - principal investigator
Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, PolandCollaborator
Medical University of GdanskOverall official - principal investigator
Medical University of LodzCollaborator
Voivodeship Hospital, Kielce, PolandCollaborator
Voivode Specialist Hospital in Olsztyn, PolandCollaborator

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.